Therapeutic Blockade of Type 2 Cytokines and PD1 Unleashes Anti-Tumor Immunity Through Coordinated Reprogramming of Innate and Adaptive Immune Surveillance
Thomas Fabre, Eleanore Hendrickson, Katherine McGourty, Paola Marcovecchio, James McMahon, Sara Patti, KaiLi Cage, Stephen C. Searles, Christella E. Widjaja, Christopher J. Stairiker, Kathryn Bound, Roxanne Martino, Edward Pyszczynski, Ying Zhang, Graham D. Thomas, , Alex Barron
This study shows that blocking type 2 cytokines and PD1 enhances anti-tumor immunity by reprogramming immune cells in both in vitro and in vivo models.
bioRxiv · Sep 26, 2025 · PreprintCancer Biology